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Sequentially randomized designs, more recently known as sequential multiple assign-
ment randomized trial (SMART) designs, are widely used in biomedical research, partic-
ularly in clinical trials, to assess and compare the effects of various treatment sequences.
In such designs, patients are initially randomized to one of the first-stage therapies. Then
patients meeting some criteria (e.g., no relapse of disease) participate in the second-stage
randomization to one of the second-stage therapies. The advantage of such a design is that
it allows the investigator to study various treatment sequences where the patients’ second-
stage therapies can be adjusted based on their responses to the first-stage therapies. In
the past few years, substantial improvement has been made in the statistical methods for
analyzing the data from SMARTs. Much of the proposed statistical approaches focus on
estimating and comparing the survival outcomes of treatment sequences embedded in the
SMART designs. In this article, we introduce the R package DTR, which provides a set
of functions that can be used to estimate and compare the effects of different treatment
sequences on survival outcomes using the newly proposed statistical approaches. The
proposed package is also illustrated using simulated data from SMARTs.
Keywords: adaptive treatment strategy, dynamic treatment regime, inverse-probability weight-
ing, survival analysis, sequential multiple assignment randomized trial (SMART) design, se-
quentially randomized design, treatment sequence.
1. Introduction
Sequentially randomized designs, more recently known as sequential multiple assignment ran-
domized trial (SMART) designs, are widely used in biomedical research, particularly in clinical
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trials, to assess and compare the effects of various treatment sequences (Robins 1986, 1987;
Lavori and Dawson 2000; Murphy 2005; Bembom and van der Laan 2007; Chakraborty and
Murphy 2013; Kidwell 2014). In such designs, patients are initially randomized to one of the
first-stage therapies. Then patients meeting some criteria (e.g., no relapse of disease) partic-
ipate in the second-stage randomization to one of the second-stage therapies. The second-
stage therapy could be a rescue therapy if patients show primary resistance to the first-stage
therapy, or a maintenance therapy if favorable responses are observed. There are different
types of SMART designs with respect to the participants in the second-stage randomization:
(i) SMART designs in which only the responders to one of the first-stage therapies partic-
ipate in the second-stage randomization to one of the maintenance therapies; (ii) SMART
designs in which only the non-responders to one of the first-stage therapies participate in the
second-stage randomization to one of the rescue therapies; (iii) SMART designs in which the
responders to all the first-stage therapies participate in the second-stage randomization; (iv)
SMART designs in which the non-responders to all the first-stage therapies participate in the
second-stage randomization; and (v) SMART designs in which all the responders and non-
responders participate in the second-stage randomization (Lei, Nahum-Shani, Lynch, Oslin,
and Murphy 2012; Chakraborty and Moodie 2013). The advantage of such a design is that
it allows the investigator to study various treatment sequences where the patients’ second-
stage therapies can be adjusted based on their responses to the first-stage therapies. Here
is an example of a SMART design investigating the effect of a combination of myeloablative
chemotherapy, total-body irradiation and transplantation of autologous bone marrow purged
of cancer cells (ABMT) to a standard chemotherapy in treating children with high risk neu-
roblastoma (Matthay et al. 1999, 2009). All the children with high risk neuroblastoma were
treated with the same initial regimen of chemotherapy, and those without disease progres-
sion participated in the first-stage randomization to either ABMT or three cycles of intensive
chemotherapy. All the children who completed cytotoxic therapy without disease progression
then participated in the second-stage randomization to either treatment with 13-cis-retinoic
acid (cis-RA) for six months or no further therapy.
In the past few years, substantial improvement has been made regarding the statistical meth-
ods for analyzing data from SMART designs in terms of either continuous outcomes (Dawson
and Lavori 2010, 2012), binary outcomes (Buyze and Goetghebeur 2013) or survival out-
comes (Lunceford, Davidian, and Tsiatis 2002; Guo and Tsiatis 2005). This article focuses
on the proposed statistical approaches for estimating and comparing the survival endpoints
of treatment sequences from these trials. Those treatment sequences are usually referred to
as dynamic treatment regimes (DTRs), adaptive treatment strategies, or treatment policies.
A DTR is defined as a sequence of the first-stage therapy, an intermediate response to the
first-stage therapy, and the second-stage therapy. The construction of DTRs is usually from
SMART designs or longitudinal observational studies. However, this article only discusses
the DTRs constructed from SMART designs. In the high risk neuroblastoma study described
above, four DTRs can be constructed: (i) treat with ABMT followed by cis-RA if no disease
progression; (ii) treat with ABMT followed by no further therapy if no disease progression;
(iii) treat with chemotherapy followed by cis-RA if no disease progression; and (iv) treat with
chemotherapy followed by no further therapy if no disease progression. Evaluating the effect
of a sequence of therapies is more efficient and more clinically meaningful than looking at the
first- and second-stage therapies separately (Chakraborty and Murphy 2013; Kidwell 2014).
Lunceford et al. (2002) introduced the survival and mean restricted survival estimators for
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treatment regimes in a two-stage randomization design using two forms of inverse-probability
weighting for second-stage randomization and censoring respectively. Guo and Tsiatis (2005)
proposed a weighted risk set estimator (WRSE) for the cumulative hazard function. Tang
and Wahed (2011) proposed a generalized Cox model for comparing any combination of treat-
ment regimes after adjustment for auxiliary variables. Kidwell and Wahed (2013) proposed
weighted log-rank test statistics to compare survival distributions of DTRs. Tang and Wahed
(2015) introduced the cumulative hazard ratio (CHR) estimator between two DTRs, and a
testing procedure to compare the effects of DTRs based on the CHR estimator.
Although we have seen considerable advancement in the development of statistical methods
for estimating and comparing the effects of DTRs on survival outcomes, no statistical package
has been developed to implement those newly-proposed statistical approaches. Investigators
and statisticians hesitate to implement the newly-proposed statistical approaches, mainly be-
cause (i) the statistical formulae for estimating and comparing the survival distributions of
DTRs are theoretically complex, and (ii) the newly-proposed statistical methodology has not
been included in any widely-used statistical software. Therefore, we developed the R package
DTR (Tang and Melguizo 2015) to implement the newly-proposed statistical approaches for
estimating and comparing the survival outcomes of different DTRs. The current version of the
package and documentation implemented the SMART designs in which the responders to all
the first-stage therapies participate in the second-stage randomization. However, it can also
be applied to SMART designs where the non-responders to all the first-stage therapies par-
ticipate in the second-stage randomization by switching the responders with non-responders.
In Section 2 we briefly introduce the notation and the formulae for calculating the survival
quantities based on each statistical method included in this version of the package. In Sec-
tion 3 the functionality of each function is described and illustrated using simulated data from
SMARTs. A more complete overview of the functionality is given in the reference manual
of the DTR package which is available from the Comprehensive R Archive Network (CRAN)
at http://CRAN.R-project.org/package=DTR. Some concluding remarks are provided in
Section 4.
2. Statistical methods for dynamic treatment regimes
2.1. Notation
In the SMART designs used for the DTR package, patients are initially randomized to J first-
stage therapies (A1, A2, . . . , AJ), then patients who responded to the first-stage therapies are
then randomized to K second-stage therapies (B1, B2, . . . , BK). The treatment regime AjBk,
where j = 1, 2, . . . , J ; k = 1, 2, . . . ,K, is defined as “treat with Aj , followed by Bk if responds
to Aj .” The primary research interest is to estimate and compare the effects of different DTRs
in terms of survival quantities (e.g., survival function, cumulative hazard function). The set
of observed data from this design can be described as
{Xji, Ri, RiTRi , RiZki, Ui,∆i, Vi},
for j = 1, 2, . . . , J ; k = 1, 2, . . . ,K; and i = 1, 2, . . . , n; where
Xji: the indicator for the jth first-stage therapy, Xji = 1 if the ith patient was assigned to
first-stage therapy Aj , and Xji = 0 if otherwise;
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Ri: the indicator for response, Ri = 1 if the ith patient responded, and Ri = 0 if otherwise;
TRi (optional): the time to response for the ith patient;
Zki: the indicator for kth second-stage therapy, Zki = 1 if the ith patient was assigned to
second-stage therapy Bk, and Ri = 1 and Zki = 0 if otherwise; (note that Ri = 0
and Zki = 0 if the ith patient did not respond, and thus did not participate in the
second-stage randomization);
Ui: the observed event/censoring time for the ith patient;
∆i: the censoring indicator, ∆i = 0 if the ith patient was censored, and ∆i = 1 if the ith
patient’s event was observed; and
Vi (optional): the covariate vector for the ith patient.
When the response status is considered as a time-varying process, we define the time-varying
response variable to be Ri(t) = RiI(T
R
i < t).
Based on the analytical framework of inverse-probability weighting (Lunceford et al. 2002;
Guo and Tsiatis 2005; Wahed and Tsiatis 2004, 2006; Tang and Wahed 2015; Kidwell and
Wahed 2013), the weight functions used by various statistical approaches for treatment regime
AjBk, j = 1, 2, . . . , J and k = 1, 2, . . . ,K are defined in Table 1. Because patients randomized
to A1, A2, . . ., and AJ are independent samples, some statistical methods (Lunceford et al.
2002; Guo and Tsiatis 2005) estimate the survival quantities for treatment regime AjBk based
on Aj data only. Based on the counting process notation described in Fleming and Harrington
(1991), the risk, event and censoring indicators used in this article are outlined in Table 2. The
survival function, cumulative hazard function, and hazard function for treatment regime AjBk
are denoted as Sjk(t), Λjk(t) and λjk(t) respectively for j = 1, 2, . . . , J and k = 1, 2, . . . ,K.
2.2. Inverse-probability weighting estimator
The survival estimator for treatment regime AjBk using the two forms of inverse-probability















I(Ui ≤ t), (1)
j = 1, 2, . . . , J and k = 1, 2, . . . ,K where K̂(t) is the Kaplan-Meier estimate of the censoring
























where L is defined as the restricted lifetime, which is smaller than the maximum follow-up
time of the SMART, and
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At-risk process at time t
Patient i Number of patients
Yi(t) = I(Ui ≥ t) Y (t) =
∑n
i=1 Yi(t)
Yji(t) = I(Ui ≥ t,Xji = 1) Yj(t) =
∑n
i=1 Yji(t)
Y NRji (t) = {1−Ri(t)}Yji(t) Y NRj (t) =
∑n
i=1{1−Ri(t)}Yji(t)
Yjki(t) = WjkiYi(t) Yjk(t) =
∑n
i=1WjkiYi(t)





Event process at time t
Patient i Number of patients
Ni(t) = I(Ui ≥ t,∆i = 1) N(t) =
∑n
i=1Ni(t)
Nji(t) = I(Ui ≥ t,∆i = 1, Xji = 1) Nj(t) =
∑n
i=1Nji(t)
NNRji (t) = {1−Ri(t)}Nji(t) NNRj (t) =
∑n
i=1{1−Ri(t)}Nji(t)
Njki(t) = WjkiNi(t) Njk(t) =
∑n
i=1WjkiNi(t)





Censoring process at time t
Patient i Number of patients





Table 2: Counting process notations.
where








I(Ui ≤ t)− 1 + Ŝjk(t)
}
I(Ui ≥ u).
The detailed steps for calculating the variance estimator are outlined in Appendix A. The
inverse-probability weighting estimator is mostly used when the primary research question
of a SMART is to estimate the survival probabilities of DTRs over time, and the time to
response is not observed or it is known that the time to response does not affect the overall
survival outcome.
2.3. Weighted risk set estimator
The weighted risk set estimator (WRSE) of the survival function for treatment regime AjBk
















































The detailed steps for calculating σ̂2 are outlined in Appendix B. The weighted risk set
estimator is mostly used when the primary research question of a SMART is to estimate the
survival probabilities of DTRs over time, and it is suspected that the time to response would
impact the overall survival outcome.
2.4. Cumulative hazard ratio estimator
Based on stratified proportional hazards with treatment regimes as strata (Tang and Wahed
2015), the hazard function for treatment regime AjBk, j = 1, . . . , J and k = 1, . . . ,K can be
written as




, j = 1, . . . , J and k = 1, . . . ,K,
where λjk0(t) is the baseline hazard function for treatment regime AjBk, and β is a vector of
coefficients corresponding to baseline covariates V . The coefficient estimate β̂ can be obtained





















p=1 Yjkp(t) exp {β>Vp}
.









Based on the estimated cumulative baseline hazards, the estimated cumulative hazard ratio





The cumulative hazard ratio estimator θ̂jkj′k′(t) follows a Gaussian process with mean θjkj′k′(t)
and variance function σ2jkj′k′(t). The detailed steps for computing the variance estimator
σ̂2jkj′k′(t) for θ̂jkj′k′(t) are described in Section 3 and Appendix B of Tang and Wahed (2015).
The cumulative hazard ratio estimator is mostly used when the primary research interest is to
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compare the survival curves of different DTRs after adjusting for other potential risk factors,
and it is suspected that the proportional hazards assumption is violated.
2.5. Wald-type test
Wald-type tests can be used for comparing the survival quantities of different treatment
regimes based on either the inverse-probability weighting estimator (Lunceford et al. 2002),
WRSE (Guo and Tsiatis 2005) or the logarithm of the CHR estimator (Tang and Wahed
2015). For example, let us denote the estimates for the survival functions to be
Ŝ(t) = {Ŝ11(t), Ŝ12(t), . . . , ŜJ(K−1)(t), ŜJK(t)},
and their estimated variance covariance matrix to be Σ̂. For testing the null hypothesis
H0 : DS(t) = 0, where D is a d× (JK) matrix, the test statistic can be written as {DŜ(t)}>
{DΣ̂D>}−1{DŜ(t)}, and it follows a chi-square distribution with d degrees of freedom. The
Wald-type test is mostly used when the primary research interest is to compare the survival
rates of different DTRs at certain times (e.g., 3-year survival, and 5-year survival).
2.6. Weighted log-rank test
Feng and Wahed (2008) introduced a supremum weighted log-rank test statistic for testing
for the survival differences between two DTRs. However, the supremum weighted log-rank
tests can only be applied for comparing two separate-path DTRs. Kidwell and Wahed (2013)
extended Feng and Wahed (2008)’s work and proposed the weighted log-rank tests for com-
paring the survival distributions of shared-path DTRs. The current version of the package
incorporated the weighted log-rank tests proposed by Kidwell and Wahed (2013). The stan-
dardized weighted log-rank test statistic for comparing treatment regime AjBk and AjBk′




















































Y ∗jk(s) + Y
∗
jk′(s)
}2 {π−2j Y NRj (s)dNj(s)Yj(s)
}
. (8)
The detailed steps for calculating ZWjkjk′(t) and σ̂
2(t) are outlined in Appendix C. The weighted
log-rank test is mostly used when the primary research interest is to compare the survival
curves of different DTRs, and there is no other risk factors to be considered.
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2.7. Generalized Cox model
For comparing the effects of different DTRs after adjustment for auxiliary variables, Tang
and Wahed (2011) proposed to use the following version of the Cox model based on two-stage
randomization designs where J = K = 2:




1 X1 + β
(2)R(t) + β
(3)
1 X1R(t) + β
(4)






where λ(t) is the general hazard function at time t; λ0(t) denotes the baseline hazard func-
tion (when all the covariates are equal to 0); R(t) denotes the time-varying measurement














. Under model (9), comparisons of treatment regimes in
terms of their hazards can be interpreted based on the coefficient vector β. For example,
for comparing all four treatment regimes in a simple two-stage randomization design, the









11 = 0. The generalized Cox model is mostly used when the
primary research interest is to compare the survival curves of different DTRs after adjusting
for other potential risk factors under the assumption of proportional hazards across regimes.
3. The DTR package
The DTR package for the R environment for statistical computing and graphics (R Core Team
2015) can be downloaded from CRAN at http://CRAN.R-project.org/package=DTR. This
package is designed for the estimation and comparison of survival distributions of DTRs from
SMARTs in which the responders to all the first-stage therapies participate in the second-
stage randomization. In SMART designs, there could be more than two therapies available
at each stage. For simplicity, and to maintain the similarity to the most common SMARTs,
a two-stage randomization design allowing for two treatment options at each stage is used
in the current version of the package. The basic structure of a SMART design used for this
package is depicted in Figure 1. In detail, patients are initially randomized to either A1 or A2
as first-stage therapy, then patients who responded to the first-stage therapies are randomized
to either B1 or B2 as second-stage therapy. Four DTRs are embedded in this design:
A1B1: treat with A1, followed by B1 if responds to A1;
A1B2: treat with A1, followed by B2 if responds to A1;
A2B1: treat with A2, followed by B1 if responds to A2; and
A2B2: treat with A2, followed by B2 if responds to A2.
The current version of the DTR package includes the functions for simulating data from
various two-stage randomization designs, estimating the survival quantities (e.g., survival
function, restricted mean survival, cumulative hazard ratio) of treatment regimes, plotting
the survival estimates over time, and comparing the survival distributions of different regimes.
The statistical approaches proposed in Lunceford et al. (2002); Guo and Tsiatis (2005); Tang
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Figure 1: The basic structure of a SMART design used for the DTR package.
and Wahed (2011, 2015); and Kidwell and Wahed (2013) are implemented in the current
version of the DTR package. A brief introduction of each statistical method is given in
Sections 2.2–2.7. For the convenience of the reader, we also summarize the functionality of
the DTR package in Table 3.
3.1. Output/input data
The data from a two-stage randomization design shown in Figure 1 is stored in an R data
frame consisting of the following arguments:
X: First-stage indicator, X = 0 if assigned to A1, and X = 1 if assigned to A2.
TR: Time to response.
R: Response status, R = 1 for responders, and R = 0 for non-responders.
Z: Second-stage indicator, R = 1 and Z = 0 if assigned to B1 (note that R = 0 and Z = 0 for
non-responders), and Z = 1 if assigned to B2.
U: Observed time, U is event time if delta = 1, and U is censoring time if delta = 0.
delta: Censoring indicator, delta = 1 for observed events, and delta = 0 for censored.
V: Covariate(s) to be adjusted. V may include one column for one covariate, or more than
one column for multiple covariates.
Because (i) only the data from the Aj arm was described in the simulation studies of Lunceford
et al. (2002) and Guo and Tsiatis (2005), (ii) the approaches described in Guo and Tsiatis
(2005) and Kidwell and Wahed (2013) treated response status as a time-varying process, (iii)
Tang and Wahed (2011) and Tang and Wahed (2015) took into account the information from
auxiliary covariates, different sets of the above arguments are generated by different data
simulation functions, and required as the input data for different estimation and comparison
functions. For clarification, we summarize the output/input data for each function in Table 4.
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Function Arguments Description
Data simulation functions
simLDTdata (n, ...) Data simulation
simWRSEdata (n, ...) Data simulation
simCHRdata (n, ...) Data simulation
simLRdata (n, ...) Data simulation
simPHdata (n, ...) Data simulation
Estimation functions
LDTestimate (data, L) Survival estimates
WRSEestimate (data) Survival estimates
CHRestimate (data, covar) Cumulative hazard ratio
estimates
S3 summary methods
for class ‘DTR’ (object, ...) Summarize ‘DTR’ object
for class ‘CHR’ (object, ...) Summarize ‘CHR’ object
S3 print methods
for class ‘DTR’ (x, ...) Print ‘DTR’ object
for class ‘summary.DTR’ (x, ...) Print ‘summary.DTR’ object
for class ‘CHR’ (x, ...) Print ‘CHR’ object
for class ‘summary.CHR’ (x, ...) Print ‘summary.CHR’ object
S3 plot methods
for class ‘DTR’ (x, ...) Survival plot
for class ‘CHR’ (x, ...) Cumulative hazard ratio plot
Comparison functions
contrast_wald (est, t) Wald-type test based on
survival estimates
contrast_chr (est, t) Wald-type test based on
cumulative hazard ratio estimates
contrast_logrank (data) Weighted log-rank test
PHfit (data, covar) Fit generalized Cox model
contrast_ph (fit) Wald-type test based on
generalized Cox model
Table 3: Summary of the functionality of the DTR package.
3.2. Inverse-probability weighting estimator functions
The function LDTestimate() computes the inverse-probability weighting survival estimates
and their estimated standard errors for DTRs at observed event times based on Equations 1
and 2. The technical details are briefly described in Section 2.2 (see more details in Lunceford
et al. 2002). The examples in this section will be illustrated using a simulated dataset called
LDTdata which is included in the DTR package. The LDTdata dataset was simulated as
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Function Input argument Output/input data
simLDTdata — {R, Z, U, delta}
simWRSEdata — {TR, R, Z, U, delta}
simCHRdata — {X, R, Z, U, delta, V}
simLRdata — {X, TR, R, Z, U, delta}
simPHdata — {X, TR, R, Z, U, delta, V}
LDTestimate data {X, R, Z, U, delta}
WRSEestimate data {X, TR, R, Z, U, delta}
CHRestimate data {X, R, Z, U, delta, V}
contrast_logrank data {X, TR, R, Z, U, delta}
PHfit data {X, TR, R, Z, U, delta, V}
Table 4: Summary of output/input data for each function.
described in the simulation study of Lunceford et al. (2002) using the simLDTdata() function
as follows.
After installing package DTR, load the package:
R> library("DTR")
Simulate the LDTdata dataset using the simLDTdata() function:
R> set.seed(123)
R> data.A1 <- simLDTdata(n = 100, max.c = 2.5, pi.r = 0.5, pi.z = 0.5,
+ lambda = 1.33, alpha = 6.67, beta1 = 0.29, beta2 = -0.67, L = 1.5)
R> data.A2 <- simLDTdata(n = 100, max.c = 2.5, pi.r = 0.5, pi.z = 0.5,
+ lambda = 1.33, alpha = 6.67, beta1 = 0.29, beta2 = -0.67, L = 1.5)
R> LDTdata <- cbind(X = c(rep(0, 100), rep(1, 100)),
+ rbind(data.A1, data.A2))
The same data set can also be loaded into the workspace using the command below:
R> data("LDTdata", package = "DTR")
The LDTdata dataset is a data frame with 200 rows corresponding to patients and 5 columns
corresponding to variables. There were 200 patients equally assigned to either A1 or A2 at
the first stage. Afterwards, 98 (49%) patients responded to either A1 or A2, and they were
then equally assigned to either B1 or B2 at the second stage. The total follow-up time was
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X R Z U delta
1 0 1 0 0.71894380 0
2 0 0 0 0.54286779 1
3 0 0 0 1.02244230 0
4 0 1 1 0.04301965 1
5 0 0 0 0.04672240 1
6 0 1 1 0.11389125 0
The function LDTestimate() creates an object of class ‘DTR’ that contains a list of components:
DTRs, the number of observation for each regime, the number of events for each regime,
observed event times, the number of patients at risk at each event time, the number of events
at each event time, the survival estimates for each regime, and their variance/covariance
estimates.
R> est <- LDTestimate(data = LDTdata)
R> est
Call: LDTestimate(data = LDTdata)
DTR records events median LCL95 UCL95
A1B1 75 54 0.8363004 0.5499846 1.0112419
A1B2 75 51 0.5245500 0.4290100 0.7144589
A2B1 77 58 0.5495142 0.4500212 0.8327760
A2B2 75 55 0.5773552 0.3939629 1.1364390
The median survival times for treatment regimes A1B1, A1B2, A2B1, and A2B2 were es-
timated to be 0.84 (95% confidence interval (CI): 0.55–1.01), 0.52 (95% CI: 0.43–0.71),
0.55 (95% CI: 0.45–0.83), and 0.58 (95% CI: 0.39–1.14) years respectively. We can call the
summary() function of the ‘DTR’ object to print a full list of the survival estimates.
R> summary(est)
Call: LDTestimate(data = LDTdata)
time n.risk n.event SURV11 SURV12 SURV21
0.003283737 199 1 0.9909211 0.9886175 1.0000000
0.004230144 198 1 0.9818422 0.9772351 1.0000000
0.004784251 197 1 0.9818422 0.9772351 0.9899313
0.006796506 196 1 0.9818422 0.9772351 0.9798627
0.017014431 195 1 0.9818422 0.9772351 0.9697940
0.018175468 194 1 0.9727633 0.9658526 0.9697940
SURV22 SE11 SE12 SE21 SE22
1.0000000 0.01008932 0.01008263 0.000000000 0.000000000
1.0000000 0.01425190 0.01423295 0.000000000 0.000000000
0.9900736 0.01425190 0.01423295 0.009984863 0.009991568
0.9801472 0.01425190 0.01423295 0.014099290 0.014118278
0.9702207 0.01425190 0.01423295 0.017241736 0.017276660
0.9702207 0.01743465 0.01739978 0.017241736 0.017276660































































































Figure 2: The inverse-probability weighting estimates under four treatment regimes based on
the simulated data. The | represents censoring.
Only the first few rows of the summary() output are shown above. The plot() function
can be used to plot the survival estimates and their corresponding 95% confidence bands of
four DTRs, displayed in Figure 2. Comparisons of survival estimates at a specific time point
can be carried out among DTRs by calling the function contrast_wald(). Both overall and
pairwise comparisons are performed.
R> contrast_wald(est, t = 1)
H0 (t=1) test statistic df p
1 A1B1=A1B2=A2B1=A2B2 7.9059901218 3 0.04799509
2 A1B1=A1B2 3.7484056950 1 0.05285791
3 A1B1=A2B1 3.1334772144 1 0.07669998
4 A1B1=A2B2 0.0019567425 1 0.96471702
5 A1B2=A2B1 0.0008756533 1 0.97639289
6 A1B2=A2B2 3.6607866126 1 0.05570733
7 A2B1=A2B2 4.1219916252 1 0.04232922
There was a significant difference in the 1-year survival among four treatment regimes (overall
p = 0.048), and patients following regime A2B2 appeared to have a better 1-year survival
compared to patients following regime A2B1 (A2B1 vs. A2B2: p = 0.04; Figure 2).
3.3. Weighted risk set estimator functions
The function WRSEestimate() calculates the weighted risk set estimates of the survival func-
tions and their estimated standard errors based on Equations 3 and 4. The technical details
are briefly described in Section 2.3 (see more details in Guo and Tsiatis 2005). The examples
in this section will be illustrated using a simulated dataset called WRSEdata which is included
in the DTR package. The WRSEdata dataset was simulated as described in the simulation
study of Guo and Tsiatis (2005) using the simWRSEdata() function.
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Load the WRSEdata dataset into the workspace:
R> data("WRSEdata", package = "DTR")
The WRSEdata dataset is a data frame with 200 rows corresponding to patients and 6 columns
corresponding to variables. In this dataset, 200 eligible patients were equally assigned to
first-stage therapy A1 or A2. All the patients were followed from the time of randomization
until they responded/did not respond to the first-stage therapy, and the time to response
varied across patients. 98 (49%) of the patients responded to the first-stage therapy, and were
further assigned to one of the second-stage therapies B1 or B2 at a 1 : 1 ratio. The maximum




X TR R Z U delta
1 0 415.28788 1 0 367.38028 0
2 0 0.00000 0 0 131.76759 1
3 0 0.00000 0 0 286.84001 1
4 0 30.20926 1 1 211.68924 1
5 0 0.00000 0 0 11.34070 1
6 0 599.66131 1 1 58.19843 0
The function WRSEestimate() creates an object of the same class ‘DTR’ as described above.
R> est <- WRSEestimate(data = WRSEdata)
R> est
Call: WRSEestimate(data = WRSEdata)
DTR records events median LCL95 UCL95
A1B1 75 60 261.4049 182.9489 386.9716
A1B2 75 57 262.6695 202.9910 416.0386
A2B1 77 60 209.5315 133.3808 312.1586
A2B2 75 57 275.8422 160.7573 441.5636
The estimated median survival times were 261 (95% CI: 183–387), 263 (95% CI: 203–416),
210 (95% CI: 133–312), and 276 (95% CI: 161–442) days for regimes A1B1, A1B2, A2B1, and
A2B2 respectively. The functions summary() and plot() can be used to display and plot the
survival estimates at observed event times respectively. The plot of the survival estimates
and their 95% confidence bands across study period is shown in Figure 3. Comparisons of
survival estimates can be carried out between different DTRs by testing the equality of the
weighted risk set estimates at a specific time point by calling the function contrast_wald().






















Figure 3: The weighted risk set estimates under four treatment regimes based on the simulated
data.
R> contrast_wald(est, t = 500)
H0 (t=500) test statistic df p
1 A1B1=A1B2=A2B1=A2B2 0.78786426 3 0.8523675
2 A1B1=A1B2 0.04674220 1 0.8288323
3 A1B1=A2B1 0.08414960 1 0.7717508
4 A1B1=A2B2 0.08279477 1 0.7735452
5 A1B2=A2B1 0.18895723 1 0.6637859
6 A1B2=A2B2 0.01882311 1 0.8908748
7 A2B1=A2B2 0.72328550 1 0.3950683
No significant difference was found in the 500-day survival among the four DTRs (overall
p = 0.85).
3.4. Cumulative hazard ratio estimator functions
Based on the statistical methods proposed in Tang and Wahed (2015), we developed the
CHRestimate() function for calculating the CHR estimates between pairwise DTRs across
times. A brief introduction of the statistical method can be found in Section 2.4. The
examples in this section will be illustrated using a simulated dataset called CHRdata which
is included in the DTR package. The CHRdata dataset was simulated as described in the
simulation study of Tang and Wahed (2015) using the simCHRdata() function.
Load the CHRdata dataset into the workspace:
R> data("CHRdata", package = "DTR")
The CHRdata dataset is a data frame with 200 rows corresponding to patients and 7 columns
corresponding to variables. In this dataset, a total of 200 eligible patients participated in
the first-stage randomization, and were equally assigned to either A1 or A2 as first-stage
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therapy. Among the 200 patients, 121 (60.5%) responded to the first-stage therapies they
were assigned to, and then participated in the second-stage randomization. At the second-
stage randomization 121 patients were equally assigned to either B1 or B2 as second-stage
therapy. Approximately 25% of the patients were censored during the 5-year study period.
The investigator suspected that gender (column V1, 1 for males and 0 for females) may have
an impact on the survival outcomes, and thus would like to adjust for the gender effect when




X R Z U delta V1 V2
1 0 1 0 4.07642397 1 0 0
2 1 1 1 1.98054567 1 1 1
3 0 1 0 2.31292696 1 0 1
4 0 1 1 3.94075459 0 1 1
5 0 1 1 3.48862215 0 1 0
6 1 0 0 0.08659921 1 0 1
The function CHRestimate() creates an object of class ‘CHR’ that contains a list of components:
coefficient estimate(s) for covariate(s), comparisons between DTRs, the 75th percentile of the
observed times, observed event times, the number of patients at risk at each event time, the
number of events at each event time, the CHR estimates, their variance/covariance estimates,
the log CHR estimates, and their variance/covariance estimates.




The gender coefficient was estimated to be 0.37. The hazards of death among males were
estimated to be 1.45 times the hazards among females.
R> est
Call: CHRestimate(data = CHRdata, covar = "V1")
comparison time75P CHR LCL95 UCL95 LOGCHR
A1B2 vs. A1B1 2.95 0.8675783 0.4858320 1.2493246 -0.1420495
A2B1 vs. A1B1 2.95 1.9842268 1.0744243 2.8940293 0.6852293
A2B2 vs. A1B1 2.95 0.5147304 0.2563395 0.7731213 -0.6641120
A2B1 vs. A1B2 2.95 2.2870867 1.2401984 3.3339751 0.8272788
A2B2 vs. A1B2 2.95 0.5932956 0.2956825 0.8909088 -0.5220625
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For example, the estimated CHR for comparing the treatment regime A2B1 to regime A1B1
was 0.87 (95% CI: 0.49–1.25) at 2.95 years. The summary() function prints the CHR estimates
(default log.CHR = FALSE) or the log CHR estimates (log.CHR = TRUE) at observed event
times.
R> summary(est, log.CHR = TRUE)
Call: CHRestimate(data = CHRdata, covar = "V1")
time n.risk n.event CHR1211 CHR2111 CHR2211
0.01370667 200 1 NA NA NA
0.02271074 199 1 NA NA NA
0.02364251 198 1 NA NA NA
0.03483425 197 1 NA NA NA
0.03876242 196 1 1.08209451 1.15707144 1.04708406
0.06430915 195 1 0.66809770 0.45782539 0.34783801
CHR2112 CHR2212 CHR2221 SE1211 SE2111
NA NA -0.1087876 NA NA
NA NA -0.1094524 NA NA
0.05929750 -0.050154913 -0.1094524 NA NA
0.46987657 0.359889189 -0.1099874 NA NA
0.07497693 -0.035010453 -0.1099874 0.9617040 1.1516823
-0.21027231 -0.320259695 -0.1099874 0.6396431 0.9123984
SE2211 SE2112 SE2212 SE2221
NA NA NA 0.1607660
NA NA NA 0.1617506
NA 1.2217712 1.2199936 0.1617506
NA 1.1521291 1.1496529 0.1625413
1.1535057 0.9463734 0.9448615 0.1625413
0.9147200 0.8462893 0.8454683 0.1625413
Only the first few rows of the summary() output are shown above. The pairwise log CHR
estimates between any two different DTRs and their 95% confidence bands can be plotted
by calling the plot() function with log.CHR = TRUE and confidence.interval = TRUE
(Figure 4). The comparisons of different treatment regimes are carried out by performing the
Wald-type tests based on the log CHR estimates by calling the contrast_chr() function.
R> contrast_chr(est, t = 3)























Figure 4: The cumulative hazard ratio estimates for comparing different treatment regimes
based on the simulated data.
H0 (t=3) test statistic df p
1 A1B1=A1B2=A2B1=A2B2 35.9076643 3 7.832658e-08
2 A1B1=A1B2 0.1009254 1 7.507219e-01
3 A1B1=A2B1 8.5797065 1 3.399302e-03
4 A1B1=A2B2 6.7235720 1 9.514688e-03
5 A1B2=A2B1 10.6019870 1 1.129662e-03
6 A1B2=A2B2 5.4159672 1 1.995340e-02
7 A2B1=A2B2 34.7604241 1 3.728768e-09
As shown in Figure 4, there was no significant difference in the 3-year survival between
treatment regimes A1B2 and A1B1 (p = 0.75). Other than that, all other treatment regimes
were significantly different from each other at 3 years (overall p < 0.001).
3.5. The weighted log-rank test function
The contrast_logrank() function was developed with regard to the statistical methods
proposed in Kidwell and Wahed (2013). We briefly introduced the methods in Section 2.6.
The examples in this section will be illustrated using a simulated dataset called LRdata which
is included in the DTR package. The LRdata dataset was simulated as described in the
simulation study of Kidwell and Wahed (2013) using the simLRdata() function.
Load the LRdata dataset into the workspace:
R> data("LRdata", package = "DTR")
The LRdata dataset is a data frame with 100 rows corresponding to patients and 6 columns
corresponding to variables. In this dataset, 100 eligible patients were equally assigned to one
of the first-stage therapies A1 or A2. They were followed until they responded to or did not
respond to the first-stage therapies. 61 (61%) responders were then equally assigned to one
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of the second-stage therapies B1 or B2. The maximum follow-up time was 12 years, and 24%




X TR R Z U delta
1 1 0.3564477 1 1 3.3707436 1
2 0 0.0000000 0 0 1.9288219 1
3 0 0.0000000 0 0 0.2135722 1
4 1 1.2715099 1 0 7.1945839 1
5 0 2.6705747 1 1 2.7690037 1
6 1 0.0000000 0 0 0.2741043 1
The contrast_logrank() function compares the survival distributions of different DTRs
using the weighted log-rank tests (Kidwell and Wahed 2013).
R> contrast_logrank(data = LRdata)
H0 (standardized) test statistic df p
1 A1B1=A1B2=A2B1=A2B2 1.2950 2 0.5234
2 A1B1=A1B2 -0.5799 1 0.5620
3 A1B1=A2B1 -0.3268 1 0.7438
4 A1B1=A2B2 0.5964 1 0.5509
5 A1B2=A2B1 0.3759 1 0.7070
6 A1B2=A2B2 0.8272 1 0.4081
7 A2B1=A2B2 1.1500 1 0.2501
We did not find any significant difference in the survival distributions of four DTRs (overall
p = 0.52).
3.6. Generalized Cox model functions
The PHfit() and contrast_ph() functions were developed with regard to the statistical
methods proposed in Tang and Wahed (2011). We briefly introduced the methods in Sec-
tion 2.7. The examples in this section will be illustrated using a simulated dataset called
PHdata which is included in the DTR package. The PHdata dataset was simulated as de-
scribed in the simulation study of Tang and Wahed (2011) using the simPHdata() function.
Load the PHdata dataset into the workspace:
R> data("PHdata", package = "DTR")
The PHdata dataset is a data frame with 400 rows corresponding to patients and 7 columns
corresponding to variables. In this dataset, 400 patients participated in the first-stage ran-
domization to either A1 or A2, and then were followed until their response status was observed
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at different times. Among 400 patients, 227 (57%) patients responded, and then participated
in the second-stage randomization to either B1 or B2. The censoring rate was 53% throughout




X TR R Z U delta V
1 1 0.0000000 0 0 0.1904523 1 0.7197622
2 1 0.0000000 0 0 1.8259748 1 0.8849113
3 0 0.5323748 1 1 1.6978088 0 1.7793542
4 1 0.0000000 0 0 0.6579115 0 1.0352542
5 0 0.0000000 0 0 2.0384931 1 1.0646439
6 1 0.0000000 0 0 4.6701414 1 1.8575325
The generalized Cox model can be fitted by calling the PHfit() function. The function
returns an object of class ‘coxph’ that is introduced in the survival package (Therneau and
Grambsch 2000; Therneau 2015). The Cox proportional hazard model output can be printed
by calling the summary() function of the ‘coxph’ object.
R> fit <- PHfit(data = PHdata, covar = "V")
R> summary(fit)
Call:
"coxph(Surv(U, delta) ~ X + R + XR + RZ + XRZ + V)"
n= 573, number of events= 187
coef exp(coef) se(coef) z Pr(>|z|)
X -0.4613 0.6305 0.1869 -2.468 0.01357 *
R -0.7918 0.4530 0.3266 -2.425 0.01532 *
XR 0.6769 1.9679 0.4263 1.588 0.11229
RZ 1.2743 3.5761 0.3557 3.583 0.00034 ***
XRZ -1.4178 0.2423 0.5105 -2.777 0.00548 **
V -0.2520 0.7772 0.1539 -1.638 0.10152
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
exp(coef) exp(-coef) lower .95 upper .95
X 0.6305 1.5862 0.43709 0.9094
R 0.4530 2.2074 0.23886 0.8592
XR 1.9679 0.5082 0.85335 4.5379
RZ 3.5761 0.2796 1.78102 7.1803
XRZ 0.2423 4.1279 0.08907 0.6589
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V 0.7772 1.2866 0.57487 1.0509
Concordance= 0.601 (se = 0.023 )
Rsquare= 0.048 (max possible= 0.968 )
Likelihood ratio test= 28.2 on 6 df, p=8.627e-05
Wald test = 29.91 on 6 df, p=4.082e-05
Score (logrank) test = 31.72 on 6 df, p=1.845e-05
We can perform the comparisons of the survival distributions among different treatment
regimes by calling the function contrast_ph() on the ‘coxph’ object returned by the PHfit()
function.
R> contrast_ph(fit)
H0 test statistic df p
1 A1B1=A1B2=A2B1=A2B2 26.7316696 4 2.252281e-05
2 A1=A2 18.9904445 3 2.746455e-04
3 B1=B2 12.9969214 2 1.505755e-03
4 A1B1=A1B2 12.8367145 1 3.398839e-04
5 A1B1=A2B1 6.4112311 2 4.053394e-02
6 A1B1=A2B2 6.1272860 2 4.671719e-02
7 A1B2=A2B1 16.5567266 2 2.539525e-04
8 A1B2=A2B2 18.6510113 2 8.912188e-05
9 A2B1=A2B2 0.1527972 1 6.958765e-01
There was a significant difference in the survival distribution among the four DTRs (overall
p < 0.001). Patients assigned to A1 at the first stage had significantly different survival
distribution compared to those assigned to A2. Among patients who were assigned to A1 at
the first stage, whether they were assigned to B1 or B2 significantly affected their survival
outcomes. However, if patients were assigned to A2 at the first stage, there was no significant
difference in the survival irrespective of their assignment at the second stage.
4. Discussion
In this article, we illustrated the DTR package designed for estimating and comparing the
effects of treatment regimes from SMARTs in the context of survival endpoints. The package
implements the statistical estimating and testing procedures proposed in Lunceford et al.
(2002); Guo and Tsiatis (2005); Tang and Wahed (2011); Tang and Wahed (2015); and Kidwell
and Wahed (2013). Each statistical method was briefly introduced, and the functionality of the
DTR package was demonstrated using the simulated data from various SMARTs as described
in aforementioned papers. The simulated datasets were generated for illustration purpose,
and may not reflect the dataset in a real-life situation. For example, in the WRSEdata and
LRdata datasets, some response times were observed after the censoring times, which may not
be realistic in SMARTs. The package allows users to perform the generation of artificial data
from SMARTs, point estimation of the survival quantities, estimates of their standard errors,
overall and pairwise comparisons of the effects of different DTRs, and a visualization of the
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survival curves for DTRs over the study period. We hope that this package can be useful
for researchers in several areas where SMART designs with survival outcomes are applicable.
Although it is still common to separately evaluate the first- and second-stage therapies when
analyzing the survival data from SMARTs, we hope that the analyses could be substantially
improved by using the functions provided by this package, as there has been a growing interest
in studying the effects of different treatment sequences in biomedical research.
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A. Computation of Equation 2
The detailed steps for computing V̂AR{Ŝjk(t)} using Equation 2 are as follows:
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B. Computation of Equation 4









































































C. Computation of Equations 7 and 8
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